Twist Bioscience Launches Mouse Exome to Power Genetic Research

SAN FRANCISCO–(BUSINESS WIRE)–#DNA–Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic DNA
using its silicon platform, today announced the launch of the Twist
Mouse Core Exome Panel, the most comprehensive, up-to-date tool for
interrogation of the mouse exome, further enabling genetic research of
this important model organism.

“We are pleased to launch our first next-generation sequencing (NGS)
product for the research market, which can be used for very specific
preclinical research for cancer and other genetic diseases,” said Emily
M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “We offer a
variety of specific and custom target enrichment panels for NGS which we
can update, iterate and customize quickly due to our proprietary
silicon-based DNA synthesis platform. The Twist Mouse Core Exome Panel
is our first non-human exome and allows us to reach not only core labs
but also independent researchers and scientists.”

The mouse is an extremely important model system for studying genetic
variation, tumor mutations, and phenotypic outcomes as well as the
therapeutic effect of pharmaceutical agents. Twist’s mouse panel
includes the most comprehensive, up-to-date content available. As
genetic variant databases are continuously updated, the Twist Mouse
Exome panel is thoughtfully designed and built from the most current
databases. When combined with Twist’s expanding portfolio of library
preparation and enrichment reagents, the complete toolset allows
researchers to achieve industry-leading coverage across target regions
while optimizing sequencing cost and sample throughput.

For more information about the Twist Mouse Core Exome Panel, please
visit our website.

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology
company that has developed a disruptive DNA synthesis platform to
industrialize the engineering of biology. The core of the platform is a
proprietary technology that pioneers a new method of manufacturing
synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging
its unique technology to manufacture a broad range of synthetic
DNA-based products, including synthetic genes, tools for next-generation
sequencing (NGS) preparation, and antibody libraries for drug discovery
and development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist makes
products for use across many industries including healthcare, industrial
chemicals, agriculture and academic research.

Follow us on Twitter
| Facebook
| LinkedIn
| YouTube


Investor Contact:
Argot Partners
Maeve Conneighton

Media Contact:
Angela Bitting

error: Content is protected !!